Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company is leveraging a proprietary data analytics platform to create a pipeline of oral tyrosine kinase 2 inhibitors and other therapies [2] - Upcoming investor conferences will feature Alumis, providing opportunities for engagement with investors [1][4] Company Overview - Alumis is developing therapies aimed at improving health outcomes for patients with immune-mediated diseases, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline includes envudeucitinib (formerly ESK-001) and A-005 for various systemic and neuroinflammatory conditions, as well as lonigutamab for thyroid eye disease [2] - The company has several preclinical programs identified through its precision approach [2] Upcoming Events - Alumis will participate in multiple investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 3 at 9:45 am ET [4] - Wells Fargo 2025 Healthcare Conference on September 5 at 9:30 am ET [4] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 4:50 pm ET [4] - H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 10:30 am ET [4] - Baird 2025 Global Healthcare Conference on September 10 at 2:35 pm ET [4] - Stifel 2025 Virtual Immunology & Inflammation Forum on September 16 at 12:30 pm ET [4]

Core Insights - Alumis Inc. has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE), with topline data expected in Q3 2026 [1][5]. Company Overview - Alumis is a late-stage biopharma company focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform [7]. - The company is developing a pipeline of oral TYK2 inhibitors, including ESK-001 for SLE and moderate-to-severe plaque psoriasis, and A-005 for neuroinflammatory and neurodegenerative diseases [7]. Clinical Trial Details - The LUMUS Phase 2b trial is a randomized, double-blind, placebo-controlled study involving 408 patients with moderately-to-severely active, autoantibody-positive SLE, assessing the efficacy of ESK-001 over 48 weeks [2][5]. - The primary endpoint of the trial is to evaluate improvements in overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48 [2][5]. Drug Mechanism and Efficacy - ESK-001 is designed to selectively target key inflammatory drivers, such as type 1 interferon (IFN), aiming for maximal inhibition while minimizing off-target effects [3][4]. - Clinical data from the psoriasis program indicates that ESK-001 downregulates key cytokines and disease biomarkers, suggesting potential to reduce SLE disease activity [4]. Future Prospects - The company anticipates that ESK-001 could provide biologic-like clinical responses for SLE, based on its performance in previous clinical studies [4].

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [3] Pipeline Development - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including ESK-001 for systemic immune-mediated disorders like moderate-to-severe plaque psoriasis and systemic lupus erythematosus [3] - A-005 is being developed for neuroinflammatory and neurodegenerative diseases [3] - The pipeline also features lonigutamab, an anti-insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs [3] Upcoming Events - Martin Babler, President and CEO of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 3:10 p.m. ET [1] - A live webcast of the presentation will be available on the Alumis website, with a replay archived for 90 days [2]

Company Overview - Alumis Inc. has completed its merger with ACELYRIN, Inc., establishing itself as a leading clinical-stage biopharma company with a differentiated portfolio of therapies and a strong balance sheet [1][3] - Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, with ACELYRIN common stock ceasing to trade on NASDAQ [2] Financial Position - The merger significantly strengthens Alumis' balance sheet, allowing for the advancement of its late-stage portfolio and the development of transformative therapies for patients [3] - Alumis now has a cash runway that extends into 2027, supporting multiple planned key data readouts [3] Product Pipeline - Alumis is developing next-generation targeted therapies for immune-mediated diseases, including oral tyrosine kinase 2 inhibitors such as ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [5] - The pipeline also includes lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs identified through a precision approach [5] Advisory Team - Morgan Stanley & Co. LLC served as the financial advisor to Alumis, while Cooley LLP acted as its legal counsel [4] - Guggenheim Securities, LLC served as the financial advisor to ACELYRIN, with Fenwick & West LLP and Paul Hastings LLP providing legal counsel [4]